Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies

Abstract

BackgroundRemnant lipoproteins (RLPs), the triglyceride‐enriched precursors to low‐density lipoprotein, are an emerging risk factor for coronary heart disease (CHD). We sought to determine the association of RLP cholesterol (RLP‐C) levels with incident CHD in 2 diverse, prospective, longitudinal observational US cohorts.Methods and ResultsWe analyzed cholesterol levels from serum lipoprotein samples separated via density gradient ultracentrifugation in 4114 US black participants (mean age 53.8 years, 64% women) from the Jackson Heart Study and a random sample of 818 predominantly white participants (mean age 57.3 years, 52% women) from the Framingham Offspring Cohort Study. Multivariable‐adjusted hazard ratios (HRs) for RLP‐C (the sum of very low‐density lipoprotein3 cholesterol and intermediate‐density lipoprotein cholesterol) were derived to estimate associations with incident CHD events consisting of myocardial infarction, CHD death, and revascularizations for each cohort separately and as a combined population. There were 146 CHD events in the combined population. After adjustments for age, sex, body mass index, smoking, blood pressure, diabetes, and lipid‐lowering therapy for the combined population, RLP‐C (HR 1.23 per 1‐SD increase, 95% CI 1.06–1.42, P<0.01) and intermediate‐density lipoprotein cholesterol (HR 1.26 per 1‐SD increase, 95% CI 1.08–1.47, P<0.01) predicted CHD during an 8‐year follow‐up. Associations were attenuated by high‐density lipoprotein cholesterol and ultimately lost significance with inclusion of real low‐density lipoprotein cholesterol, which excludes Lp(a) and IDL cholesterol fractions. Similar associations were seen in multivariable analyses within each cohort.Conclusion RLP‐C levels are predictive of incident CHD in this diverse group of primary prevention subjects. Interventions aimed at reducing RLP‐C to prevent CHD warrant further intensive investigation.Clinical Trial Registration URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00415415.

Risk factors for the treatment outcome of retreated pulmonary tuberculosis patients in China: an optimized prediction model

“…Our findings add novel insights for the prognosis and treatment of retreated PTB patients in China and throughout the world. The Optimized Framingham Heart Profile (FHP) is widely used in various fields [16], including stroke, coronary heart disease, metabolic syndrome, hypertension, TB, and other diseases [17][18][19][20][21][22]. In addition, optimized FHP was also used to predict the risk of bacteremia for TB patients with HIV, which showed that predicted probability of bacteremia for TB patients with HIV increased with increasing risk score.…”

Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias

“…Classically, lipids have been measured after an overnight fast and the resultant profiles used to characterize dyslipidemias and predict risk of CHD. However, recent investigations have explored whether fasting is essential to classify an individual's risk status, and indeed the extent to which a non-fasting test provides a superior index of risk (4,(11)(12)(13)(14). Recently, the…”

“…Particles from both sources are believed to be atherogenic since they contain apoB (VLDL remnants have apoB100, and chylomicron remnants apoB48, as the major structural protein), a cholesterol 'payload', and can permeate the arterial wall subendothelial space where lesion formation is initiated (11,12). There is increasing evidence that the plasma concentration of remnants is related to CHD risk independent of LDLc level (4,(11)(12)(13)(14).…”

Could remnant-like particle cholesterol become a risk factor in diabetic menopausal women with coronary artery disease? A cross-sectional study of single academic center in China

“…For CAD patients with decreased LDL-C, it is found that RLP-C may be an important target for the treatment of blood lipids in CAD patients after treatment of LDL-C [2]. RLP-C levels could also be used to predict the onset of CAD in different populations, thus confirming that RLP-C measurement is beneficial for risk assessment and treatment assessment of CAD patients [3]. Although RLP-C is a risk factor for cardiovascular related atherosclerotic disease, there is currently no standard method of measurement and the research potential of RLP-C is huge [4].…”